MARINUS PHARMACEUTICALS INC (MRNS)

Company Profile

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 165 full-time employees. The company went IPO on 2014-07-31. The firm is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The firm is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). The company is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Company Info

MARINUS PHARMACEUTICALS INC

5 Radnor Corporate Center Suite 500, 100 Matsonford Rd

Radnor PENNSYLVANIA 19087

P: 14848014670

CEO: Scott Braunstein

Employees: 165

Website: https://marinuspharma.com/